Introduction
There is a quiet revolution happening in cardiology. For decades, the story was simple: cholesterol clogs arteries. Lower cholesterol, and you lower risk. Statins became the cornerstone of prevention, and for many people, they reduced LDL levels significantly.
But a problem persisted. Even with LDL well controlled, some people kept having heart attacks. Studies confirmed what observant clinicians already suspected: there is a residual cardiovascular risk that LDL lowering alone does not address .
The culprit, increasingly, is lipoprotein(a)—Lp(a). Unlike ordinary LDL, Lp(a) is a sticky, more dangerous particle. It is now recognized as an independent, causal risk factor for atherosclerotic cardiovascular disease . Approximately one in five people worldwide has elevated Lp(a), yet fewer than 1% have ever been tested .
The 2026 ACC/AHA guidelines have changed that. Universal Lp(a) testing is now recommended. Millions of people will soon learn their Lp(a) levels for the first time. Many will discover they are high.
When they do, their doctors will face a dilemma. There is currently no drug approved specifically to lower Lp(a) . Statins, the foundation of lipid management, do not lower Lp(a). In fact, some studies suggest they may modestly raise it by 10–20% .
This is where PCSK9 inhibitors enter the conversation.
What PCSK9 Inhibitors Actually Do
PCSK9 inhibitors—drugs like evolocumab (Repatha) and alirocumab (Praluent)—are a newer class of lipid-lowering therapy. They work by blocking the PCSK9 protein, which normally degrades LDL receptors on liver cells. By inhibiting PCSK9, these drugs allow more LDL receptors to remain active, clearing more LDL cholesterol from the blood .
The results are impressive. PCSK9 inhibitors can reduce LDL cholesterol by 50–60% on top of statin therapy .
But LDL is not the only thing these drugs affect. Clinical trials noticed something else: PCSK9 inhibitors also lower Lp(a).
The reduction is approximately 20–30% . A meta-analysis of 10 randomized controlled trials found that the mean Lp(a) reduction with PCSK9 inhibitors was 19.3%, representing an absolute drop of roughly 6.7 mg/dL .
This is a real effect. It is statistically significant. It has generated considerable excitement in the cardiology community because it represents the first pharmacologic approach that both lowers Lp(a) and reduces cardiovascular risk .
But is a 20–30% reduction enough?
The Gap Between Lowering a Number and Solving the Problem
Let me put this in perspective.
If your Lp(a) is 125 nmol/L—the threshold now considered elevated by the 2026 guidelines—a 25% reduction brings it to about 94 nmol/L. That is still above the level associated with lower cardiovascular risk.
If your Lp(a) is 250 nmol/L—a level at which cardiovascular risk at least doubles—a 25% reduction brings it to 188 nmol/L. You are still firmly in the danger zone.
If your Lp(a) is 400 nmol/L, a 25% reduction brings it to 300 nmol/L. You have simply moved from “extremely high” to “very high.”
This is the fundamental limitation of relying on PCSK9 inhibitors to address Lp(a)-related risk. Lowering a number by a fraction is not the same as correcting the reason it is elevated.
The medical literature itself acknowledges the gap. A 2025 review in Clinica Chimica Acta noted that “the mechanism by which PCSK9 inhibitors reduce Lp(a) levels remains unknown” . Another review in the European Heart Journal concluded that for patients with extremely high Lp(a) levels (above 200 nmol/L), “the absolute reduction often fails to reach the expected risk-balance threshold” .
In plain language: for the people who need Lp(a) lowering the most, PCSK9 inhibitors do not lower it enough.
Why PCSK9 Inhibitors Are Not the Complete Answer
Beyond their limited Lp(a) reduction, there are additional concerns that should give any thoughtful patient pause.
Cost and Access
PCSK9 inhibitors are expensive. When they were first introduced, their high price and the modest cardiovascular benefit seen in clinical trials led to significant barriers. Insurance coverage was inconsistent. A 2025 analysis found that fewer than 1% of eligible patients with ASCVD were receiving PCSK9 inhibitors, and only about 49.9% of prescriptions were covered by insurance .
Mechanism Uncertainty
We know PCSK9 inhibitors lower Lp(a). But as the scientific literature openly admits, we do not know how. The mechanism remains unclear. Most experimental evidence points to enhanced clearance of Lp(a) particles through non-LDL receptor pathways, but the specific process remains unidentified . You are being prescribed a drug whose mechanism of action on Lp(a) is not understood.
Lp(a) Reduction Is a Secondary Effect
PCSK9 inhibitors were designed to lower LDL, not Lp(a). The Lp(a) reduction is a fortunate side effect, not a targeted therapy. The drugs are not approved specifically for Lp(a) lowering, and their effect on Lp(a) was discovered incidentally in clinical trials .
Modest Absolute Reductions
The numbers bear repeating. A 19.3% mean reduction. Approximately 6.7 mg/dL absolute decrease . For someone with very high Lp(a), this is like emptying a swimming pool with a teaspoon. It is technically progress. It is not a solution.
The Deeper Question: Why Is Lp(a) Elevated in the First Place?
This is where conventional medicine and root-cause medicine diverge completely.
Conventional medicine sees elevated Lp(a) as a problem to be suppressed. It identifies the marker, looks for a drug to lower it, and measures success by the percentage reduction.
Root-cause medicine asks a different question: Why is your body producing so much Lp(a)?
Lp(a) is not a random genetic error. It is not a metabolic mistake. It is a repair particle.
Your artery walls are made of collagen—a tough, flexible protein that requires vitamin C to form properly. When vitamin C is deficient over many years, the collagen weakens. Microscopic cracks develop in the endothelial lining. Your liver responds by producing Lp(a), a sticky particle designed to patch those cracks. Over decades, layer upon layer of these patches builds up into what we call arterial plaque.
A 1990 US patent proved this directly. Using gel electrophoresis, researchers showed that the primary component of human atherosclerotic plaque is Lp(a)—not ordinary LDL cholesterol.
Your Lp(a) is not high because your body is malfunctioning. It is high because your body is responding to structural weakness in your artery walls. The Lp(a) is the band-aid. The real problem is the crack.
A PCSK9 inhibitor can reduce the number of band-aids circulating in your blood by 20%. It cannot fix the crack.
Lowering vs. Normalizing: A Completely Different Philosophy
There is a profound difference between lowering a marker and normalizing the underlying process.
When you take a PCSK9 inhibitor, you are intervening in a metabolic pathway to reduce the number of Lp(a) particles in circulation. The mechanism is pharmacologic blockade—preventing the degradation of LDL receptors so more particles are cleared from the blood .
When you address the root cause, you are providing the nutrients your artery walls need to repair themselves. Vitamin C activates the enzymes that build collagen. Lysine and proline supply the structural material. The cracks in the artery wall begin to heal. The signal that tells your liver to produce excess Lp(a) diminishes. Lp(a) levels may normalize—not because you blocked something, but because your body no longer needs to produce so much.
One approach manages a number. The other restores function.
This is not alternative medicine. It is biochemistry.
What My Book Offers That a Prescription Cannot
I learned this lesson in the most direct way possible—through my own heart disease.
In 2010, I was diagnosed with two coronary artery blockages above 80%. Bypass surgery was recommended. I refused. As a PhD medicinal chemist trained at the Central Drug Research Institute, I had the training to investigate why arteries truly fail.
What I found—the connection between vitamin C deficiency, collagen weakness, and Lp(a) repair—changed my life. I formulated a protocol to provide my arteries with the nutrients they had been missing. I took it consistently.
Today, at 75, I take no heart medications. My heart functions well. I am not an exception. I am someone who addressed the root cause.
My book, Reverse Heart Disease: No Lifelong Suffering, explains this science in full. It provides the complete protocol—which nutrients, why they matter, and how to use them. It is written for people who have been told their Lp(a) is high and that nothing can be done.
PCSK9 inhibitors have a role in modern cardiology. For some patients, they are an appropriate part of lipid management. But they are not a cure. They do not address why your Lp(a) is elevated. They lower a number without fixing the underlying problem.
If you are satisfied with a 20% reduction and a lifetime of injections, you have that option.
If you want to understand why your Lp(a) is high and what your body actually needs to repair itself, my book is for you.
Dr. Balaram Dhotre is a PhD medicinal chemist, cellular nutritionist, and the author of Unraveling the Root Cause of Chronic Diseases and Reverse Heart Disease: No Lifelong Suffering. He writes at lyproc.com to help people understand the true root cause of chronic illness and reclaim their health.
[Click here to get your copy of Reverse Heart Disease: No Lifelong Suffering on Amazon]
——————————————————————————————————————————–
My Books
Links on Amazon
Unraveling The Root Cause of Chronic Diseases:
Reverse Heart Disease: No Lifelong Suffering
————————————————————————————————————————–